High-throughput screening against protein:protein interaction interfaces reveals anti-cancer therapeutics as potent modulators of the voltage-gated Na+ channel complex
Open Access
- 15 November 2019
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-15
Abstract
Multiple voltage-gated Na+ (Nav) channelopathies can be ascribed to subtle changes in the Nav macromolecular complex. Fibroblast growth factor 14 (FGF14) is a functionally relevant component of the Nav1.6 channel complex, a causative link to spinocerebellar ataxia 27 (SCA27) and an emerging risk factor for neuropsychiatric disorders. Yet, how this protein:channel complex is regulated in the cell is still poorly understood. To search for key cellular pathways upstream of the FGF14:Nav1.6 complex, we have developed, miniaturized and optimized an in-cell assay in 384-well plates by stably reconstituting the FGF14:Nav1.6 complex using the split-luciferase complementation assay. We then conducted a high-throughput screening (HTS) of 267 FDA-approved compounds targeting known mediators of cellular signaling. Of the 65 hits initially detected, 24 were excluded based on counter-screening and cellular toxicity. Based on target analysis, potency and dose-response relationships, 5 compounds were subsequently repurchased for validation and confirmed as hits. Among those, the tyrosine kinase inhibitor lestaurtinib was highest ranked, exhibiting submicromolar inhibition of FGF14:Nav1.6 assembly. While providing evidence for a robust in-cell HTS platform that can be adapted to search for any channelopathy-associated regulatory proteins, these results lay the potential groundwork for repurposing cancer drugs for neuropsychopharmacology.Keywords
Funding Information
- Pharmaceutical Research and Manufacturers of America Foundation (RSGPT18)
- University of Texas System (Rising Stars Award)
- Cancer Prevention and Research Institute of Texas (RP150578)
- Foundation for the National Institutes of Health (R01 MH111107, R01 MH095995)
This publication has 63 references indexed in Scilit:
- Bioluminescence Methodology for the Detection of Protein–Protein Interactions Within the Voltage-Gated Sodium Channel Macromolecular ComplexASSAY and Drug Development Technologies, 2012
- Spinocerebellar ataxias type 27 derived from a disruption of the fibroblast growth factor 14 gene with mimicking phenotype of paroxysmal non-kinesigenic dyskinesiaBrain and Development, 2012
- RAF protein-serine/threonine kinases: Structure and regulationBiochemical and Biophysical Research Communications, 2010
- FGF14 N-terminal splice variants differentially modulate Nav1.2 and Nav1.6-encoded sodium channelsMolecular and Cellular Neuroscience, 2009
- Crystal Structure of a Fibroblast Growth Factor Homologous Factor (FHF) Defines a Conserved Surface on FHFs for Binding and Modulation of Voltage-gated Sodium ChannelsJournal of Biological Chemistry, 2009
- Small Molecule Protein–Protein Interaction Inhibitors as CNS Therapeutic Agents: Current Progress and Future HurdlesNeuropsychopharmacology, 2008
- Functional properties and differential neuromodulation of Nav1.6 channelsMolecular and Cellular Neuroscience, 2008
- TNF‐mediated inflammatory diseaseThe Journal of Pathology, 2007
- The channelopathies: novel insights into molecular and genetic mechanisms of human diseaseJournal of Clinical Investigation, 2005
- Differential activation of nuclear factor‐κB by tumour necrosis factor receptor subtypes. TNFR1 predominates whereas TNFR2 activates transcription poorlyFEBS Letters, 2002